Skip to main content
Caplight Logo









Reapplix

Reapplix

Private
DenmarkHealthcare & Life Scienceshttps://reapplix.com/

Last Round

Series B

Jul 14, 2020

Total Funding Raised

$22.6M

Company Overview

Reapplix is a regenerative medicine company that develops and manufactures the 3C Patch System, an innovative biological wound therapy for the treatment of hard-to-heal diabetic foot ulcers.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

wound careregenerative medicineautologous therapypoint-of-carewound healingchronic wound treatmentmedical devicePRFplatelet-rich fibrinmedtechbiologicsbiotechdiabetic foot ulcerbiomaterials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Reapplix Comparables

Compare Reapplix with similar companies based on industry and business-model similarity.

Reapplix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RedDress
90%
Velora Wound Care
85%
Nuo Therapeutics Inc
82%

Reapplix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 14, 2020
VC RoundSep 27, 2016

Key People

Founding team and executive leadership

Kira Rupprecht

Chief Executive Officer and Board Member

Executive Team

Morten Have-Rasmussen

CFO

Executive Team

Carsten Heinze

Chief Operating Officer

Executive Team

Reapplix Investors

Notable investors and investment history

Reapplix investors
InvestorRounds
Lauxera Capital PartnersSeries B
Novo HoldingsSeries B
SEED CapitalVC Round
North-East Health Care Investment ApSSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 14, 2020

    $23M round with participation from Novo Holdings and Lauxera Capital Partners.

  • Sep 27, 2016

    $3M round led by Novo Holdings and SEED Capital.

Reapplix Filings

Explore SEC and related filing metadata, where available.

Reapplix filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Reapplix's valuation, stock price, and market status.

Is Reapplix a public or private company?

Reapplix is a private company.

What is the current stock price of Reapplix?

Reapplix is a private company with no public stock price. No recent secondary market data is available.

How much is Reapplix worth (valuation)?

Valuation information for Reapplix is not publicly available.

Can I buy Reapplix stock?

Reapplix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Reapplix's last funding round?

Reapplix's most recent funding round was Series B on July 14, 2020.

Who are the main investors in Reapplix?

Key investors in Reapplix include Lauxera Capital Partners, Novo Holdings, SEED Capital, North-East Health Care Investment ApS.

Will Reapplix IPO soon?

No public IPO plans have been announced for Reapplix.

How can I track Reapplix secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Reapplix's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDenmark
Employee Range31
Year Founded2008
Last FundingJul 14, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?